Image Image Image Image Image Image Image Image Image Image
Accessibilité
Haut de page

Up

Oral Omega 3 GA. A phase II in subjects with geographic atrophy secondary to AMD
26/03/2013

Foto49_3

 

Description

A phase II, randomized, double masked clinical trial to establish the safety and efficacy of high oral doses of Omega-3 in patients with geographic atrophy secondary to dry age-related macular degeneration.

Key inclusion criteria

Patients with geographic atrophy secondary to dry age-related macular degeneration.

 

Objectives

The objectives of this study are to evaluate the safety and efficacy of High-Dose Oral Omega 3 on the Photoreceptors/Retinal Pigment Epithelium/Bruch’s membrane complex in subjects with geographic atrophy secondary to age-related macular degeneration and to evaluate whether improvement in visual function occurs and progression to advanced stages of AMD is delayed.

DrMarch_2red

If you are interested in taking part in a clinical trial, please fill in this form to contact us or call +34 935 950 155

Our team of professionals will answer you as soon as possible and we will assess whether you are eligible. 

 

Injections intravitréennesDMLA « sèche » ou atrophiqueDMLA exsudative ou humideRétinographieAutofluorescenceMicropérimétrieAngiographie en fluorescenceTomographie par cohérence optique

Author

Dr Jordi Monés, médecin, titulaire d’un doctorat
Inscrit à l'ordre des médecins de Barcelone, sous le numéro 22838
Directeur
Docteur en médecine et chirurgie
Spécialiste en ophtalmologie
Spécialiste de la rétine, de la macula et du vitré

Last modified: 22 July, 2019 - 13:01